Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies

Cancer

Volumn 113, Issue 2, 2008, Pages 360-366

  Borthakur, Gautam ^a   Alvarado, Yesid ^a   Ravandi Kashani, Farhad ^a   Cortes, Jorge ^a   Estrov, Zeev ^a   Faderl, Stefan ^a   Ivy, Percy ^b   Bueso Ramos, Carlos ^a   Bekele, B Nebiyou ^a   Giles, Francis ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Leukemia; Phase 1; Rebeccamycin analog; XL119

Indexed keywords

CASPASE 3; HYDROXYUREA; REBECCAMYCIN; VASCULOTROPIN; XL 119;

ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLAST CELL; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPOTENSION; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TUMOR LYSIS SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; BACTERIAL INFECTIONS; BIOPSY; BONE MARROW; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSIDES; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; VIRUS DISEASES;

EID: 48249151700     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23559     Document Type: Article

References (20)

1. Anizon F, Belin L, Moreau P, et al. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J Med Chem. 1997;40:3456-3465.
2. Anizon F, Moreau P, Sancelme M, et al. Syntheses, biochemical and biological evaluation of staurosporine analogues from the microbial metabolite rebeccamycin. Bioorg Med Chem. 1998;6:1597-1604.
3. Bailly C, Qu X, Anizon F, Prudhomme M, Riou JF, Chaires JB. Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue. Mol Pharmacol. 1999;55:377-385.
4. Bush JA, Long BH, Catino JJ, Bradner WT, Tomita K. Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiot (Tokyo). 1987;40:668-678.
5. Division of Cancer Treatment. Rebeccamycin analogue BMY-27557-14 Clinical Brochure. Bethesda, MD: National Cancer Institute; 1995.
6. Pereira ER, Belin L, Sancelme M, et al. Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase 1 and protein kinase C inhibition and antitumoral and antimicrobial properties. J Med Chem. 1996;39: 4471-447.
7. Weitman S, Moore R, Barrera H, Cheung NK, Izbicka E, Von Hoff DD. In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors. J Pediatr Hematol Oncol. 1998;20:136-139.
8. Long BH, Rose WC, Vyas DM, Matson JA, Forenza S. Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles. Curr Med Chem Anticancer Agents. 2002;2:255-266.
9. Dowlati A, Hoppel CL, Ingalls ST, et al. Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for 5 consecutive days. J Clin Oncol. 2001;19:2309-2318.
10. Tolcher AW, Eckhardt SG, Kuhn J, et al. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol. 2001;19:2937-2947.
11. Merchant J, Tutsch K, Dresen A, et al. Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Clin Cancer Res. 2002;8:2193-2201.
12. Korkolopoulou P, Apostolidou E, Pavlopoulos PM, et al. Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia. 2001;15:1369-1376.
13. Aguayo A, Kantarjian HM, Estey EH, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 2002;95: 1923-1930.
14. Cortes J, Kantarjian H, Albitar M, et al. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2003;97:1234-1241.
15. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene. 2002;21:8786-8803.
16. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419-425.
17. Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870-185.
18. Dias S, Shmelkov SV, Lam G, Rafii S. VEGF promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood. 2002;99:2532-2540.
19. Aref S, Mabed M, Sakrana M, Goda T, El-Sherbiny M. Soluble hepatocyte growth factor (sHGF) and vascular endothelial growth factor (sVEGF) in adult acute myeloid leukemia: relationship to disease characteristics. Hematology. 2002;7:273-279.
20. Hu Q, Dey AL, Yang Y, et al. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer. 2004;100:1884-1891.